Biomedical Research Education & Training
Faculty Member

Puzanov, Igor, M.D.
Associate Professor of Medicine

Lab Url: N/A

Phone Number: 615-322-4967

Email Address: igor.puzanov@vanderbilt.edu

Puzanov, Igor's picture
Academic history
M.D., Charles University, Prague, Czechoslovakia

Office Address   Mailing Address

777 PRB 6307


Patient Care Specialty
Phase I drug development, Renal cell carcinoma, Melanoma

Clinical Interests
Development of novel therapies for patients with solid tumors including melanoma and renal cell carcinoma

Publications
Cho, DC, Hutson, TE, Samlowski, W, Sportelli, P, Somer, B, Richards, P, Sosman, JA, Puzanov, I, Michaelson, MD, Flaherty, KT, Figlin, RA, Vogelzang, NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer, 2012

Kwa, M, Baumgartner, R, Shavit, L, Barash, I, Michael, J, Puzanov, I, Kopolovic, J, Rosengarten, O, Blank, S, Curtin, JP, Gabizon, A, Muggia, F. Is Renal Thrombotic Angiopathy a Potential Problem in the Chronic Treatment of Ovarian Cancer. Oncologist, 2012

Margolin, K, Ernstoff, MS, Hamid, O, Lawrence, D, McDermott, D, Puzanov, I, Wolchok, JD, Clark, JI, Sznol, M, Logan, TF, Richards, J, Michener, T, Balogh, A, Heller, KN, Hodi, FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol, 13(5), 459-65, 2012

McArthur, GA, Puzanov, I, Amaravadi, R, Ribas, A, Chapman, P, Kim, KB, Sosman, JA, Lee, RJ, Nolop, K, Flaherty, KT, Callahan, J, Hicks, RJ. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol, 30(14), 1628-34, 2012

Patrawala, S, Puzanov, I. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol, 8(5), 509-23, 2012

Poprach, A, Pavlik, T, Melichar, B, Puzanov, I, Dusek, L, Bortlicek, Z, Vyzula, R, Abrahamova, J, Buchler, T, , . Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol, 2012

Rosen, LS, Puzanov, I, Friberg, G, Chan, E, Hwang, YC, Deng, H, Gilbert, J, Mahalingam, D, McCaffery, I, Michael, SA, Mita, AC, Mita, MM, Mulay, M, Shubhakar, P, Zhu, M, Sarantopoulos, J. Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res, 18(12), 3414-27, 2012

Sosman, JA, Kim, KB, Schuchter, L, Gonzalez, R, Pavlick, AC, Weber, JS, McArthur, GA, Hutson, TE, Moschos, SJ, Flaherty, KT, Hersey, P, Kefford, R, Lawrence, D, Puzanov, I, Lewis, KD, Amaravadi, RK, Chmielowski, B, Lawrence, HJ, Shyr, Y, Ye, F, Li, J, Nolop, KB, Lee, RJ, Joe, AK, Ribas, A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med, 366(8), 707-14, 2012

Su, F, Viros, A, Milagre, C, Trunzer, K, Bollag, G, Spleiss, O, Reis-Filho, JS, Kong, X, Koya, RC, Flaherty, KT, Chapman, PB, Kim, MJ, Hayward, R, Martin, M, Yang, H, Wang, Q, Hilton, H, Hang, JS, Noe, J, Lambros, M, Geyer, F, Dhomen, N, Niculescu-Duvaz, I, Zambon, A, Niculescu-Duvaz, D, Preece, N, Robert, L, Otte, NJ, Mok, S, Kee, D, Ma, Y, Zhang, C, Habets, G, Burton, EA, Wong, B, Nguyen, H, Kockx, M, Andries, L, Lestini, B, Nolop, KB, Lee, RJ, Joe, AK, Troy, JL, Gonzalez, R, Hutson, TE, Puzanov, I, Chmielowski, B, Springer, CJ, McArthur, GA, Sosman, JA, Lo, RS, Ribas, A, Marais, R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med, 366(3), 207-15, 2012

Chung, CH, Pohlmann, PR, Rothenberg, ML, Burkey, BB, Parker, J, Palka, K, Aulino, J, Puzanov, I, Murphy, B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck, 33(12), 1804-8, 2011 PMCID:3111896

Puzanov, I, Burnett, P, Flaherty, KT. Biological challenges of BRAF inhibitor therapy. Mol Oncol, 5(2), 116-23, 2011

Puzanov, I, Lee, W, Chen, AP, Calcutt, MW, Hachey, DL, Vermeulen, WL, Spanswick, VJ, Liao, CY, Hartley, JA, Berlin, JD, Rothenberg, ML. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res, 17(11), 3794-802, 2011 PMCID:3107910

Bollag, G, Hirth, P, Tsai, J, Zhang, J, Ibrahim, PN, Cho, H, Spevak, W, Zhang, C, Zhang, Y, Habets, G, Burton, EA, Wong, B, Tsang, G, West, BL, Powell, B, Shellooe, R, Marimuthu, A, Nguyen, H, Zhang, KY, Artis, DR, Schlessinger, J, Su, F, Higgins, B, Iyer, R, D''Andrea, K, Koehler, A, Stumm, M, Lin, PS, Lee, RJ, Grippo, J, Puzanov, I, Kim, KB, Ribas, A, McArthur, GA, Sosman, JA, Chapman, PB, Flaherty, KT, Xu, X, Nathanson, KL, Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467(7315), 596-9, 2010 PMCID:2948082

Flaherty, KT, Puzanov, I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol, 80(5), 638-46, 2010 PMCID:3111896

Flaherty, KT, Puzanov, I, Kim, KB, Ribas, A, McArthur, GA, Sosman, JA, O''Dwyer, PJ, Lee, RJ, Grippo, JF, Nolop, K, Chapman, PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 363(9), 809-19, 2010 PMCID:2948082

Puzanov, I, Flaherty, KT. Targeted molecular therapy in melanoma. Semin Cutan Med Surg, 29(3), 196-201, 2010 PMCID:3107910

Shepherd, C, Puzanov, I, Sosman, JA. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep, 12(3), 146-52, 2010 PMCID:3111896

Su, Y, Amiri, KI, Horton, LW, Yu, Y, Ayers, GD, Koehler, E, Kelley, MC, Puzanov, I, Richmond, A, Sosman, JA. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res, 16(1), 348-57, 2010 PMCID:3205975

Sosman, J, Puzanov, I. Combination targeted therapy in advanced renal cell carcinoma. Cancer, 115(10 Suppl), 2368-75, 2009 PMCID:3205975

Tolcher, AW, Sarantopoulos, J, Patnaik, A, Papadopoulos, K, Lin, CC, Rodon, J, Murphy, B, Roth, B, McCaffery, I, Gorski, KS, Kaiser, B, Zhu, M, Deng, H, Friberg, G, Puzanov, I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol, 27(34), 5800-7, 2009 PMCID:3205975

Wade Calcutt, M, Lee, W, Puzanov, I, Rothenberg, ML, Hachey, DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom, 43(1), 42-52, 2008 PMCID:3205975

Sosman, JA, Puzanov, I, Atkins, MB. Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer. Clin Cancer Res, 13(2), 764s-769s, 2007

Sosman, JA, Puzanov, I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res, 12(7 Pt 2), 2376s-2383s, 2006

Gruber, HE, Puzanov, IJ, Bennett, M, Kumar, V, Gordon, B. Alterations in osteoclast morphology following long-term 17beta-estradiol administration in the mouse. BMC Cell Biol, 2, 3, 2001 PMCID:29068

Sivakumar, PV, George, T, Puzanov, IJ, Williams, NS, Stepp, S, Liu, J, Schatzle, J, Lai, WC, Bennett, M, Kumar, V. Hybrid resistance by mouse NK cells in vitro. Methods Mol Biol, 121, 73-9, 2000

Williams, NS, Klem, J, Puzanov, IJ, Sivakumar, PV, Bennett, M, Kumar, V. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J Immunol, 163(5), 2648-56, 1999

Sivakumar, PV, Puzanov, I, Williams, NS, Bennett, M, Kumar, V. Ontogeny and differentiation of murine natural killer cells and their receptors. Curr Top Microbiol Immunol, 230, 161-90, 1998

Sivakumar, PV, Williams, NS, Puzanov, IJ, Schatzle, JD, Bennett, M, Kumar, V. Development of self-recognition systems in natural killer cells. Adv Exp Med Biol, 452, 1-12, 1998

Williams, NS, Klem, J, Puzanov, IJ, Sivakumar, PV, Schatzle, JD, Bennett, M, Kumar, V. Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunol Rev, 165, 47-61, 1998

Puzanov, IJ, Williams, NS, Schatzle, J, Sivakumar, PV, Bennett, M, Kumar, V. Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in. Res Immunol, 148(3), 195-201, 1997

Williams, NS, Moore, TA, Schatzle, JD, Puzanov, IJ, Sivakumar, PV, Zlotnik, A, Bennett, M, Kumar, V. Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J Exp Med, 186(9), 1609-14, 1997 PMCID:2199105

Puzanov, IJ, Bennett, M, Kumar, V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol, 157(10), 4282-5, 1996


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
07/20/2012